title: [XELOX plus Bevacizumab Chemotherapy for a Patient with Postoperative Recurrence of Colorectal Cancer Under Hemodialysis for Chronic Renal Failure].
abstract: We report the case of a patient with a postoperative recurrence of colon cancer who received XELOX plus bevacizumab chemotherapy whilst undergoing hemodialysis. A 73-year-old man had been receiving maintenance hemodialysis for 9 years due to chronic renal failure. At 64 years old, a Hartmann's operation and a posterior segment and segment 3 partial liver resection were performed for sigmoid colon cancer and metastatic liver cancer. Three years 1 months after surgery, local recurrence at the liver invading into the right lung was detected. XELOX plus bevacizumab chemotherapy was administered. After 16 courses of treatment, tumor control was achieved. Chemotherapy with molecular target drugs is currently recommended for advanced/metastatic colorectal cancer; however, a standardized strategy for hemodialysis patients is not established. As the number of hemodialysis patients receiving chemotherapy for some cancers is likely to increase in the future, it will be necessary to consider chemotherapy strategies for hemodialysis patients.
authors.affiliation: Dept. of Surgery, National Hospital Organization Osaka National Hospital.
authors.forename: Takashi
authors.initials: T
authors.lastname: Takeda
authors.forename: Masakazu
authors.initials: M
authors.lastname: Miyake
authors.forename: Kiyo
authors.initials: K
authors.lastname: Tanaka
authors.forename: Mamoru
authors.initials: M
authors.lastname: Uemura
authors.forename: Masataka
authors.initials: M
authors.lastname: Ikeda
authors.forename: Sakae
authors.initials: S
authors.lastname: Maeda
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Naoki
authors.initials: N
authors.lastname: Hama
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nishikawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Miyamoto
authors.forename: Michihiko
authors.initials: M
authors.lastname: Miyazaki
authors.forename: Motohiro
authors.initials: M
authors.lastname: Hirao
authors.forename: Shoji
authors.initials: S
authors.lastname: Nakamori
authors.forename: Mitsugu
authors.initials: M
authors.lastname: Sekimoto
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D000069287:Capecitabine; D003082:Colectomy; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006498:Hepatectomy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008297:Male; D010071:Oxaloacetates; D012008:Recurrence; D006435:Renal Dialysis; D012811:Sigmoid Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D010071:Oxaloacetates; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil